Skip to main content
Year archive

4SC AG — 2017 filings

All 55 regulatory filings released by 4SC AG (VSC) in 2017, sourced directly from the official regulator.

55 Filings
2017 Period
2017 filings (55)
Filing Released Lang
4SC receives Pediatric Investigation Plan Waiver for resminostat in CTCL from the European Medicines Agency
Regulatory Filings
2017-12-20 English
Report Publication Announcement 2017
Report Publication Announcement
2017-12-19 English
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements
2017-12-19 English
Hinweis auf Halbjahresfinanzbericht vom 01.01.2018 bis zum 30.06.2018
Report Publication Announcement
2017-12-19 German
Datum:19.12.2017
Report Publication Announcement
2017-12-19 German
4SC receives milestone payment from Immunic
Regulatory Filings
2017-12-13 English
4SC AG: Significant milestone reached for pivotal RESMAIN study of resminostat as maintenance therapy in CTCL
Regulatory Filings
2017-12-05 English
DGAP-DD: 4SC AG english
Director's Dealing
2017-12-04 English
DGAP-DD: 4SC AG english
Director's Dealing
2017-11-07 English
First patient enrolled in Phase Ib/II study SENSITIZE of 4SC-202 in melanoma
Regulatory Filings
2017-11-06 English
4SC AG: 10 upcoming conferences and investor events
Regulatory Filings
2017-11-02 English
4SC provides Q3 and 9M 2017 update
Report Publication Announcement 9M 2017
2017-10-26 English
Q3 statement / Q3 financial report 2017
Interim / Quarterly Report 9M 2017
2017-10-26 English
4SC AG: Resminostat demonstrates potential to significantly alleviate itching in CTCL patients
Regulatory Filings
2017-10-10 English
Phase I study of 4SC's resminostat indicates efficacy in biliary tract cancer
Regulatory Filings
2017-09-13 English
4SC to present at upcoming scientific conferences
Regulatory Filings
2017-08-31 English
4SC provides Q2 and 6M 2017 update
Earnings Release H1 2017
2017-08-10 English
Datum:10.08.2017
Interim / Quarterly Report H1 2017
2017-08-10 German
Half-yearly financial report 2017
Interim / Quarterly Report H1 2017
2017-08-10 English
4SC AG: Conference call to be hosted on 10 August 2017 to present the half-year financial report 2017
Report Publication Announcement
2017-08-03 English
4SC AG was granted a fundamental composition of matter patent for 4SC-208 for the US
Regulatory Filings
2017-08-01 English
DGAP-DD: 4SC AG english
Director's Dealing
2017-07-24 English
4SC licenses Kv1.3 inhibitors to Maruho
Regulatory Filings
2017-07-18 English
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements
2017-07-14 English
4 SC AG: Bekanntmachung der Einberufung zur Hauptversammlung am 25.08.2017 in Planegg-Martinsried mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information
2017-07-14 German
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements
2017-07-14 English
Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2017-07-13 English
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements
2017-07-13 English
DGAP-DD: 4SC AG english
Director's Dealing
2017-07-13 English
DGAP-DD: 4SC AG english
Director's Dealing
2017-07-11 English
DGAP-DD: 4SC AG english
Director's Dealing
2017-07-11 English
4SC AG secures EUR 41 million from successful capital increase
Capital/Financing Update
2017-07-06 English
4SC AG announces subscription price for new shares from current capital increase
Capital/Financing Update
2017-06-28 English
4SC AG resolves to issue new shares to continue to advance its drug development programs for resminostat, 4SC-202 and 4SC-208
Capital/Financing Update
2017-06-12 English
4SC AG: Resminostat enhances immune cell cancer cell interaction
Regulatory Filings
2017-05-30 English
4SC AG announces updated and progressive development program
Share Issue/Capital Change
2017-05-16 English
4SC AG announces updated and progressive development program
Share Issue/Capital Change
2017-05-16 English
Jahresabschluss zum Geschäftsjahr vom 01.01.2016 bis zum 31.12.2016
Annual Report FY 2016
2017-05-05 German
4SC AG: Progress update on pivotal RESMAIN study of resminostat in CTCL at 13th Congress of the EADO
Regulatory Filings
2017-05-03 English
4SC provides Q1 2017 update
Earnings Release Q1 2017
2017-04-27 English
Q1 statement / Q1 financial report 2017
Interim / Quarterly Report Q1 2017
2017-04-27 English
Konzernabschluss zum Geschäftsjahr vom 01.01.2016 bis zum 31.12.2016
Annual Report FY 2016
2017-04-26 German
4SC AG: New mechanistic insights into 4SC-202's epigenetic mode of action
Regulatory Filings
2017-04-11 English
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements
2017-04-04 English
Declaration of Voting Results & Voting Rights Announcements 2017
Declaration of Voting Results & Voting Rights Announcements
2017-04-04 English
Annual financial report 2016
Annual Report FY 2016
2017-03-31 English
Annual financial report 2016
Annual Report FY 2016
2017-03-31 German
4SC AG announces results for financial year 2016
Earnings Release FY 2016
2017-03-29 English
4SC AG: Conference call to be hosted on 29 March 2017 to present annual results 2016
Regulatory Filings
2017-03-22 English
4SC-202 - a promising combination partner for cancer treatment
Regulatory Filings
2017-03-21 English
Report Publication Announcement 2017
Report Publication Announcement
2017-02-17 English
Report Publication Announcement 2017
Report Publication Announcement
2017-02-17 English
Hinweis auf Jahresfinanzbericht vom 01.01.2016 bis zum 31.12.2016
Report Publication Announcement
2017-02-17 German
Datum:17.02.2017
Report Publication Announcement
2017-02-17 German
4SC AG: Overall survival benefit for resminostat in first-line liver cancer study subgroup
Regulatory Filings
2017-01-24 English